more japan sales data, page-5

Esc, as mentioned by Muzza and Company, DS cant sell Inavir for stockpiling until they get Inavir approved for prevention (as opposed to treatment).

DS' first trial for prevention was botched due to under powering. I am hoping this severe flu season will be sufficient to get the powering they require.

Tooluck, yup I hear you. The first couple of quarters would have involved Inavir filling shelves for the first time. We need a few more quarters to get a clear sales trend but I think we are looking pretty.

To bet Piper Jaffray have similar cheat sheets to show prospective corporate types to illustrate Inavir can be the ducks nuts.